EP4353724A1 — Compound as cdk kinase inhibitor and use thereof
Assigned to TYK Medicines Inc · Expires 2024-04-17 · 2y expired
What this patent protects
The present invention relates to a compound as a CDK kinase inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I), wherein the definitions of each group and each substituent are as described in the description. …
USPTO Abstract
The present invention relates to a compound as a CDK kinase inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I), wherein the definitions of each group and each substituent are as described in the description. Further disclosed in the present invention are a method for preparing the compound and the use of the compound in regulating a CDK kinase activity or treating diseases related to CDK.
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.